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Abstract
Schizophrenia (SCZ) is a heterogeneous neurodevelopmental disorder that afflicts 
about 1% of the world population, imposing a huge financial and social burden 
on the community. Schizophrenia is characterized by three core features, positive 
(e.g.,  hallucinations, delusions) and negative symptoms (e.g., emotional blunting, 
reduced motivation), as well as cognitive impairments (i.e., working memory and 
attention deficits). Current antipsychotic treatments, which primarily target dopamine 
receptors, are effective at alleviating positive symptoms. However, dopamine‐specific 
therapies are insufficient to relieve negative symptoms and cognitive impairments, 
indicating other neuronal systems are involved in SCZ. Evidence for hypofunction‐
ing glutamate and gamma‐aminobutyric acid (GABA) transmission in forebrain tissue 
has continued to culminate as major contributors to the onset of SCZ. Furthermore, 
recent genetic studies reveal disrupted mutations in neurodevelopmental proteins at 
glutamatergic and GABAergic synapses that are potentially responsible for the syn‐
aptic abnormalities seen in the disorder. Therefore, schizophrenia symptomatology 
is influenced by interactions of several neurotransmitter systems. In this chapter, we 
focus on how glutamatergic and GABAergic hypofunctioning contribute to the variety 
of symptoms presented in SCZ and its etiology. We also review the current treatment 
options with respect to their mechanism of action, side effects, and limitations and 
provide perspective of where research should be directed to move forward with treat‐
ing this debilitating disease.
Keywords: neurodevelopment, glutamate, GABA, negative symptoms, cognitive deficits, 
treatment, schizophrenia
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1. Introduction
Schizophrenia is a chronic mental disorder that afflicts approximately 1.1% of the population 
worldwide. Patients not only experience physical and mental disabilities, but also impose a 
large financial burden that consumes an estimated over $60 billion in costs per year, including 
more than $20 billion in treatment in the United States of America alone.
Schizophrenic patients exhibit an array of clinical symptoms that consist of positive symp‐
toms, negative symptoms, and cognitive impairments. Due to the heterogeneity in symp‐
tomatology, this disorder is difficult to diagnose and treat. Typically, the onset of symptoms 
occurs between adolescence and early adulthood, mostly within the age range of 16–30 years 
old, occurring in men (average 18) earlier than women (average 25). Cognitive and social 
deficits are the first symptoms to appear and exacerbate over time. Individuals display a lack 
of attention, short‐term and long‐term memory loss, as well as lack of executive functions that 
include disorganized thoughts and planning. In addition, patients have difficulties commu‐
nicating ideas and notions, consequently leading to social withdrawal. As the individual gets 
older, negative symptoms appear, including a blunted affect of normal behavior and feelings. 
For instance, patients will express a lack in motivation and/or pleasure that often leads to 
depression and mood swings. Positive symptoms develop later and signify an escalated state 
of mind and altered reality, such as hallucinations, delusions, and false ideas. The amalgama‐
tion of these symptoms persist into adulthood and may perhaps lead to other comorbidities 
such as attention deficit hyperactive disorder (ADHD), depression, anxiety, aggression, and 
substance abuse [1].
Unfortunately, schizophrenia is challenging to diagnose due to the various signs and symp‐
toms; however, neuroanatomical evidence displays structural aberrations in specific tis‐
sues that assist in characterizing the disorder. For instance, postmortem patients show an 
overall decrease in brain volume and more specifically reduced cortical gray matter in fore‐
brain tissue, such as the dorsolateral prefrontal cortex (dlPFC), superior temporal gyrus, 
and limbic areas (i.e., hippocampal formation, anterior cingulate cortex). Other anatomi‐
cal anomalies include enlarged cerebral ventricles, such as the lateral and third ventricles. 
Lastly, at the cellular level, there are reports of reduced neuronal number and dendritic 
spine densities in the hippocampus and dorsolateral prefrontal cortex [2, 3], although this 
observation appears to be controversial. Nevertheless, numerous studies have confirmed a 
significant decrease in pyramidal dendritic spines within superficial layers of the prefron‐
tal cortex [2, 4].
The neurophysiological changes are equally as detrimental as the structural changes 
observed in schizophrenic patients. For example, the most prevailing theories describing the 
etiology of schizophrenia is the “Dopamine hypothesis,” which predicts dopamine imbal‐
ances within the mesocortical and mesolimbic pathways underlie schizophrenia pathology. 
Specifically, dopamine deficiency from mesocortical projecting neurons to the prefrontal 
 cortex results in “hypostimulation” of D1‐receptor neurons that contribute to the negative 
symptoms and cognitive impairments. In contrast, an excess of dopamine to the  prefrontal 
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cortex and striatum from mesolimbic dopamine pathways induces “hyperstimulation” of 
D2‐receptor neurons, responsible for the positive symptoms [5]. Therefore, current treat‐
ments target dopamine receptors, but leave other pathophysiological mechanisms untar‐
geted. Typical and atypical antipsychotics, such as haloperidol and clozapine, respectively, 
block D2‐receptors to alleviate psychotic symptoms. However, dopamine‐specific targeted 
therapy is insufficient to relieve other aspects of the disease; therefore, additional neuronal 
systems are likely involved.
In recent years, evidence has linked glutamatergic and GABAergic systems to the pathology 
of schizophrenia. An emerging hypothesis of schizophrenia suggests that N‐methyl‐D‐aspar‐
tate (NMDA) receptor hypofunction plays a major role in the dysregulation of GABAergic 
transmission, thereby contributing to the symptoms [6]. In this chapter, we discuss the struc‐
ture and function of NMDA and gamma‐aminobutyric acid (GABA) receptors, including the 
effects of genetic abnormalities on them and their associated posttranslational modifications 
and signal transduction pathways. We will also include the reviewed literature describing 
the multiple neuronal subtypes and circuits involved in schizophrenia and potential thera‐
peutic options.
2. Glutamate hypothesis of schizophrenia
Glutamate is an excitatory neurotransmitter that can act on four major classes of receptors, 
which are either metabotropic or ionotropic. Metabotropic receptors are G‐protein coupled 
receptors. Metabotropic glutamate receptors are composed of mGluR1‐8 subunits and have 
seven transmembrane segments that are connected to heterotrimeric G proteins. The remain‐
ing three classes are ionotropic receptors, or ion‐gated channels, that consist of NMDA, 
AMPA, and kainite receptors, which are readily distinguished by agonists, antagonists, kinet‐
ics, and permeability. Ionotropic glutamate receptors are composed of a tetramer of four 
subunits, with each representative monomer consisting of three transmembrane segments, 
a large extracellular glutamate‐binding domain, and a cytosolic loop that lines the channel 
pore (Figure 1).
NMDA receptor hypofunction has long been proposed as one of the major hypothesis for 
the pathophysiology of schizophrenia [6]. NMDA receptors are highly abundant within the 
forebrain and are responsible for regulating a variety of neuronal pathways; theoretically, 
damage to the glutamatergic system could underlie many pathologies of the central nervous 
system. Accordingly, there is an overwhelming amount of evidence illustrating that NMDA 
receptor dysfunction contributes to the neurophysiology associated with schizophrenia [6, 7]. 
For instance, in postmortem subjects with schizophrenia, disruptive mutations of NMDA 
receptor subunits were revealed in the prefrontal cortex, hippocampus, and thalamus [8, 9]. 
Furthermore, it is well established that administering noncompetitive NMDA receptor antag‐
onists such as phencyclidine (PCP), MK‐801 (also known as Dizocilpine), and ketamine can 
mimic the pathophysiology and behavioral attributes of schizophrenia [10–12]. Therefore, 
treatments that target to improve NMDA receptor function demonstrate an alleviation of 
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schizophrenic symptoms [13, 14]. Finally, genes implicated in schizophrenia have strong 
associations with NMDA receptor regulation [15–17].
3. The NMDA receptor structure and function
NMDA receptors are typically located on excitatory glutamatergic synapses, although present 
in many cell types (i.e., GABAergic neurons, dopaminergic neurons, etc.). NMDA receptors 
are responsible for synaptic plasticity and cortical development, as well as cognitive pro‐
cesses such as learning and working memory [18]. NMDA receptors are a heterotetrameric 
complex that consists of an obligatory homodimer of NR1 and homodimers or heterodimers 
of either combination of NR2A‐D or NR3A‐D subunits (Figure 2). The NMDA channel is 
voltage‐dependent and ligand‐gated, and highly permeable to Na+, K+, and Ca2+, causing 
depolarization of a cell and subsequent excitation and activation of intracellular signaling 
pathways. Although NR1 subunits are required for NMDA receptor function, NR2/NR3 sub‐
units are specialized and critical for functional diversity such as calcium permeability, decay 
time, open channel time, and pharmacology sensitivity. In addition, NR1 and NR2 subunits 
Figure 1. Illustration of prototypic ionotropic receptor subunit. A subunit consists of a large extracellular N‐terminus 
domain, a membrane spanning segment (TM1), a segment that partially enters the membrane (TMII), a glutamate‐
binding domain, two more membrane spanning segments, and an intracellular c‐terminus.
Schizophrenia Treatment - The New Facets4
contain distinct sites that bind glycine, PCP, and Mg2+ that modulate the activity of NMDA 
receptors (Figure 2).
4. The NMDA receptor development
Developmentally, there is an NR2B‐ to NR2A‐subunit switch that occurs from childhood‐to‐
adulthood in most brain regions that facilitate synaptic maturation [19]. NR2B protein expres‐
sion levels are highly abundant during early development and decline into adulthood; in 
contrast, NR2A levels begin low and rise in adult. Both subunits are essential for prefrontal 
synaptic plasticity and function; however, NR2B plays a more dominant role. For instance, in 
the prefrontal cortex, NR2B levels remain high into adulthood and are important for working 
memory function [20, 21]. NR2B‐containing NMDA receptors play a major role in calcium 
(Ca+) influx at the postsynaptic membrane, as NR2B receptors have slower kinetics, thus a 
slower decay time compared to NR2A‐containing NMDA receptors. This indicates that NR2B 
receptors conduct a large amount of Ca+ and Na+ due to the prolonged open channel state. 
Although NR2B is essential for cognition processes within the adult, an overabundance may 
be hazardous due to the significant increase in Ca+ conductance that could lead to excitotox‐
icity and neuronal death [21]. Therefore, NR2B/NR2A composition during development is 
extremely critical for normal synaptic maturation.
Figure 2. Schematic diagram depicting a NMDA receptor complex. Glutamate binds at NR2/NR3 complex and co‐
agonist glycine or 
D
‐serine binds at NR1 complex. Upon depolarization, Mg2+ is removed. NMDA receptor permeates 
Na+ and Ca+ influx and K+ efflux upon activation. Binding sites for PCP, ketamine, and MK801 are included (Figure was 
modified from Snyder et al. [6] and Cioffi et al. [14]).
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5. NMDA receptor dysregulation and hypofunction in schizophrenia
A major finding discovered by functional imaging studies was reduced activity in the 
dorsolateral prefrontal cortex (dlPFC) in patients with schizophrenia. The overall reduc‐
tion in neuronal activity in the dlPFC could explain the cognitive deficits and negative 
symptoms. There is consensus that NMDA receptor hypofunction is strongly associated 
with the pathophysiology of schizophrenia. In human studies, single‐photon emission 
computed tomography (SPECT) shows “hypofrontality” patients suffering from schizo‐
phrenia [22]. Furthermore, there are genetic implications that show single‐nucleotide 
polymorphisms (SNPs) and a reduction in NR1 protein and mRNA in the dorsolateral 
prefrontal cortex in postmortem subjects of schizophrenia [9, 23]. Additionally, exome 
sequencing of patients with schizophrenia also displays disruptive mutations in genes 
that encode NMDAR subunits and NMDA receptor‐associate scaffolding proteins, such as 
PSD‐95 and SAP102 [24, 25]. These findings would suggest a lack of and/or function at the 
postsynaptic membrane of excitatory synapses that could be responsible for the cellular 
phenotypes of the disorder.
Noncompetitive NMDA receptor antagonists such as PCP, MK‐801, and ketamine have been 
extensively used to study the symptoms associated with schizophrenia in both human sub‐
jects and animal models [26]. Indeed, these studies have shown to mimic the effects of schizo‐
phrenia, corroborating the glutamatergic hypofunction hypothesis. Individually, PCP induces 
psychotic symptoms in healthy humans that resemble schizophrenic‐like behavior; MK‐801 
elicits positive and negative symptoms; and lastly ketamine administration was shown to 
imitate the positive, negative, and cognitive deficits seen in schizophrenia [11]. In rats, NMDA 
receptor antagonists cause deficits in working memory, executive functions, and enhanced 
locomotor activity [27].
6. High‐risk genes implicated in schizophrenia
High‐risk genes associated with schizophrenia such as DISC1, dysbindin, neuregulin, 
COMT, and G72/G30 genes, responsible for neurodevelopment, neuronal growth, and 
migration, have all shown to be involved in NMDA dysfunction leading to schizophre‐
nia [15]. The most prominent of the genes is Disrupted in schizophrenia 1 (DISC1), which 
acts as a scaffolding protein involved in the formation of protein complexes important 
in neurodevelopment, microtubule network dynamics and axonal elongation [28, 29]. 
Despite the controversy and debate [16, 30], evidence shows that schizophrenic patients 
contain DISC1‐SNPs that cause a decrease in DISC1‐interacting protein expression levels, 
such as NMDA receptors. In DISC1 animal models, mice with point mutations in the gene 
or truncated forms of DISC1 display molecular, cellular, and behavioral phenotypes that 
are analogous to schizophrenia. DISC1 is especially susceptible to mutations due to envi‐
ronmental stressors during neurodevelopment that may lead to the pathogenesis of the 
disorder [31, 32].
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7. Other factors affecting NMDA receptor function
Environmental factors during development, such as infection, drug use, parental age, prena‐
tal and early postnatal or childhood stress, have all been linked to the emergence of schizo‐
phrenia [33]. In addition, NMDA receptor function is susceptible to the latter environmental 
risk factors during adolescence, potentially contributing to the onset of the disorder [6, 33, 34]. 
This could be due to an alteration in NMDA receptor gene expression, as major transcrip‐
tional factors such as the cAMP response element binding protein (CREB) are extremely sen‐
sitive to environmental stimuli [35]. Previous studies describe that neurodevelopment in the 
prefrontal cortex is altered in patients with schizophrenia due to a substantial increase in 
synaptic elimination of glutamatergic excitatory synapses [36].
NMDA receptors are also influenced by posttranslational modifications such as ubiquitina‐
tion, palmitoylation, and phosphorylation [34]. NMDA receptor phosphorylation is respon‐
sible for regulating receptor trafficking, stabilization, kinetics of the channel, and kinase 
activation. These processes are important for synaptic plasticity during neurodevelopment 
and if dysregulated could be highly responsible for the pathologies of schizophrenia [7]. 
NMDA receptor subunits are phosphorylated at serine/threonine and tyrosine residues, 
providing substrate sites for kinases such as Src family of kinases (SFK), casein kinase 2 
(CK2), cAMP‐dependent protein kinase A (PKA), cyclin‐dependent kinase 5 (Cdk5), pro‐
tein kinase C (PKC), and Ca2+/calmodulin‐dependent protein kinase II (CaMKII) [37–40].
Other modification processes such as palmitoylation and ubiquitination have also been 
directly linked to schizophrenia [41]. There is evidence of NMDA receptor dysregulation 
due to anomalous modifications that could potentially lead to neuropsychiatric disorders. 
Palmitoylation is a process that allows the covalent attachment of palmitate group to the cys‐
teine residues of proteins that are facilitated via thioester bonds. Recently, it has shown to 
be involved in regulating NR2 subunit trafficking during neurodevelopment and synaptic 
plasticity [42] and is altered in a mouse model of 22q11.2 deletion syndrome. Ubiquitination 
is a process involved in the targeting and removal of proteins and is responsible for regulating 
NMDA receptors degradation during development. Specifically, subunits such as NR1 and 
NR2B undergo polyubiquitination at the synapse [41]. Nonetheless, palmitoylation and ubiq‐
uitination require further investigation in its role in NMDA receptor regulation and potential 
implication in schizophrenia.
8. Intracellular mechanisms affecting NMDA receptor function
Selective intracellular signal transduction pathways, such as the AKT‐GSK3β pathway, at 
excitatory glutamatergic synapses regulate NMDA receptor functions, and are associated 
with high‐risk genes involved in schizophrenia. AKT, also known as protein kinase B, is a 
serine/threonine kinase involved in neuronal plasticity, migration, protein synthesis, and cell 
death [43, 44]. Glycogen synthase kinase 3β (GSK3β) is also a serine/threonine kinase that is 
downstream of AKT and upstream of beta‐catenin [45]. Moreover, GSK3β knockdown leads 
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to a reduction in NMDA receptor current [46]. AKT phosphorylation is a negative regulator of 
GSK3β activity; similarly, GSK3β phosphorylation induces beta‐catenin degradation. High‐
risk genes such as DISC1, dysbindin and NRG1 are all modulators of the AKT‐GSK3β signal‐
ing pathway [34]. For instance, reduced DISC1 protein expression causes a decrease in AKT 
phosphorylation, and thus an increase in GSK3β activity [47]. In addition, reducing GSK3β 
activity can alleviate the behavioral impairments observed in DISC1 mouse models [48, 49]. 
These data suggest a link between high‐risk schizophrenia genes and intracellular pathways, 
such as the AKT‐GSK3B signaling pathway, that regulate neuronal plasticity. Theoretically, 
it can be assumed that the high‐risk schizophrenia genes would affect the AKT‐GSK3β sig‐
naling pathway, and thus cause NMDA receptor dysfunction, leading to aberrant neuronal 
systems that are responsible for the positive, negative, and cognitive symptoms observed in 
schizophrenia.
9. Drug treatment that targets NMDA receptors
Typically, drug treatment for schizophrenia patients consists of antipsychotics, such as clo‐
zapine, that target D2 receptors to relieve the positive symptoms. However, a significant 
portion of schizophrenia subjects do not respond well to D2 antagonists; moreover, the nega‐
tive and cognitive impairments are barely affected by treatment with antipsychotic drugs. 
As a result, medical professionals are testing new pharmacological agents that target NMDA 
receptors as a therapeutic option. Due to the observed glutamate hypofunction impairment in 
patients, investigative studies have focused on the enhancement of NMDA receptor function. 
Therefore, high doses of glycine agonists (60 g/day) that act upon the glycineB modulatory site are used to increase NMDA receptor function [13]. These agonists have been shown to mod‐
estly improve the negative and positive symptoms of schizophrenia and are currently being 
utilized as an adjunctive treatment to primary therapy with D2 antagonists. An alternative 
option is to target the glycine transporter‐1 (GlyT‐1) with the selective inhibitor, sarcosine, 
to increase glycine availability for NMDA receptor binding [14]. Sarcosine administered at 
2 g/day have shown to improve negative and cognitive symptoms of schizophrenia. Other 
drugs include d‐Serine and d‐amino acid oxidase (DAAO) inhibitors to increase d‐Serine 
 availability, as it is considered a co‐agonist to NR1. The effects of the inhibitor were shown 
to alleviate negative and cognitive impairments in patients when administered at high doses 
(>2 g/day) and as a supplement to antipsychotic treatments [14]. Kynurenine aminotransfer‐
ase II (KATII) inhibitors are used to block kynurenic acid (an endogenous antagonist at the 
NR1 glycineB site) used to improve negative symptoms. NR2 subtype selective modulators are still under drug development and could prove beneficial to a neurological disorder, such 
as schizophrenia. Other pharmacological drugs available that affect glutamate transmission 
are utilized to target AMPA receptors, mGlu5 receptors, and NMDA receptors on GABAergic 
interneurons. However, many of these new therapeutic interventions are still in clinical trials, 
whether they are more effective than the typical and atypical D2‐related antipsychotic drugs 
remains to be determined.
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10. Glutamate‐GABA association in schizophrenia
It is theorized that NMDA dysfunction in neuronal subtypes of GABAergic and dopaminergic 
neurons collectively contribute to the neuropathologies of schizophrenia. More specifically, 
investigators speculate that NMDA receptor hypofunction occurs on GABA interneurons 
(see Figure 1 in [6]). Glutamatergic neurons have direct interaction with GABA interneu‐
rons, such as basket and chandelier cells, within the cortico‐limbic circuitry. These inter‐
neurons are responsible for suppressing output from glutamate‐releasing pyramidal cells, 
and due to recurrent collaterals from the two cell types, causes an inhibitory feedback loop. 
However, if GABAergic activity were suppressed, due to NMDAR dysfunction, it would lead 
Figure 3. Cross‐connections between NMDA receptors, GABAergic neurotransmission, and PFC‐dependent cognition. 
PFC persistent neuronal firing is the foundation of working memory with NMDA receptor activity playing a substantial 
role in this process [50, 51]. NMDA antagonism in conscious behaving monkeys impairs prefrontal‐dependent working 
memory [52] and induces cognitive impairments in healthy human subjects [11, 53–56], demonstrating a parallel between 
NMDA hypofunctioning and cognition deficits. This ‘online’ persistent neural activity is critical for working memory, 
which is not only NMDAR‐dependent, but also requires fast and synchronous inhibition of prefrontal pyramidal 
neuronal networks by GABAergic interneurons. GABAergic neurotransmission ultimately drives working memory 
function through the shaping and synchronization of pyramidal cell output. PV cortical interneurons are especially 
fundamental for generating fast gamma oscillations, which has been demonstrated in humans to be necessary for proper 
working memory [57]. NMDARs and GABAergic interneurons are interrelated because NMDA receptors play a large 
role in the maturation [58] and maintenance of interneurons, especially the NR2A subunit [59].
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to disinhibition of pyramidal neurons and excessive firing within the cortico‐limbic circuit. 
Physiologically, the excitotoxicity could have multiple effects on circuitry such as changes 
in membrane potential, receptor desensitization, or cell death. These results would have a 
twofold effect; first, the GABAergic downregulation would lead to negative symptoms and 
cognitive deficits. And second, the resulting excess glutamate release of cortico‐pyramidal 
neurons could activate dopaminergic systems that lead to positive symptoms and further 
cognitive impairments. The glutamate‐GABA systems in the forebrain, especially prefrontal 
cortex, are intertwined to produce prefrontal‐dependent cognitive function, as proposed in 
Figure 3. Still, how these two systems interact to induce phenotypes and symptoms in schizo‐
phrenia remains to be determined.
11. GABAergic cortical interneurons
Cortical interneurons were first documented with Golgi staining by Santiago Ramón y Cajal 
and referred to as the “cells with short axons” [60]. Cortical interneurons are typically distin‐
guished by four common attributes: locally projecting, aspiny or sparsely spiny dendrites, small 
cell soma, and GABAergic. Interneurons exhibit a large diversity and are categorized based on 
several features including morphology, connectivity, neurochemistry, and physiology [60–62] 
(Figure 4). Due to the heterogeneity of this neuronal population, interneurons can fall into more 
than one category, showing a great degree of overlap; therefore, interneurons fall more along a 
spectrum rather than into distinct subgroups. Although this group is very diverse, axonal arbo‐
rization and the downstream target domain plays a major role in classification and can reveal 
a lot about a circuitry's function. Essentially, where and how an interneuron synapses onto a 
target cell ultimately effects neuronal output and therefore  function [61], is an essential ques‐
tion for cortical function. Interneurons are crucial for synchronizing and shaping the excitatory 
activity of pyramidal cells to form a ‘task‐specific microcircuit’ for a particular brain region [61]; 
the prefrontal cortex contains this microcircuit specialized for working memory [62].
Three common GABAergic neocortical interneurons that will be highlighted and addressed 
in this chapter are neurochemically defined based on the calcium‐binding proteins they 
express: calbindin (CB), calretinin (CR), and parvalbumin (PV) neurons. Calbindin interneu‐
rons (also referred to as somatostatin) makeup ~30% of the cortical interneuronal  population 
and are generally characterized as having either small basket or Martinotti morphology. 
Commonly, small basket cells target proximal dendrites or the cell soma and electrophysi‐
ologically display regular‐spiking non‐pyramidal (RSNP) activity. Martinotti interneurons 
exhibit a burst‐spiking non‐pyramidal (BSNP) firing phenotype and target distal dendrites. 
Calretinin interneurons are the least prevalent (~15%) and stereotypically have small bipolar 
morphology. These interneurons target proximal dendrites and also other GABAergic inter‐
neurons having either RSNP or BSNP firing. Parvalbumin interneurons are fast‐spiking cells 
and neurochemically the largest group, making up half of the interneuronal population in 
the cortex. PV interneurons target all along a pyramidal cell, with large basket cells at the 
proximal dendrites/soma, nest cells at the soma, and chandelier cells targeting the axon initial 
 segment. For the remainder of this section, we will focus on parvalbumin chandelier cells 
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since these are the interneurons known to play a major role in prefrontal cortex‐dependent 
working memory and also have been implicated in the pathophysiology of neuropsychiatric 
disorders such as schizophrenia [60, 62].
Figure 4. Cortical interneuron connectivity and firing patterns categorized by calcium‐binding neurochemical markers. 
Calretinin small bipolar cells target proximal dendrites and other GABAergic interneurons. Calbindin neurons, small 
basket cells, and Martinotti cells, target proximal dendrites/soma and distal dendrites. Parvalbumin interneurons are 
fast‐spiking and are further classified into large basket, nest basket, and chandelier (Ch) cells. Large basket cells target 
proximal dendrites and the soma. Nest basket cells target the cell soma and chandelier cells synapse on the axon initial 
segment (Modified from Lewis et al. [62]).
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12. GABA receptor classification and structure
GABA receptors respond to the ligand GABA, which is the main inhibitory neurotransmit‐
ter in the mammalian central nervous system. GABAergic neurons are therefore important 
for modulating neuronal activity throughout the brain and spinal cord [63–70]. The enzyme 
L‐glutamic acid decarboxylase (GAD) synthesizes GABA in presynaptic terminals through 
the conversion of glutamate to GABA. GABA is then stored in vesicles waiting for release 
following neuronal activation [67]. Extracellular GABA can bind to either postsynaptic or 
extrasynaptic receptors located on presynaptic neurons, leading to hyperpolarization of the 
target cell [69]. Postsynaptic receptor activation mediates phasic inhibition, whereas extrasyn‐
aptic activation mediates a tonic inhibitory state [65, 69]. To remove extracellular GABA in the 
synaptic cleft, GABA transporters located on the presynaptic terminal and glial cells regulate 
neurotransmitter uptake; this process is extremely important to retain a balanced circuitry 
and prevent over inhibition [67].
GABA receptors are classified into two groups, GABAA and GABAB, with GABAC receptors recently categorized as a subtype of GABAA rather than their own distinct class. Receptor characterization is based on structural, biochemical, modulatory, and physiological differ‐
ences [67–70].
GABAA receptors are ionotropic chloride channels, conducting fast inhibitory neurotransmis‐sion, in which a ligand (i.e., GABA) binds and directly induces pore opening [67, 69]. GABAA receptors are members of a much larger group referred to as the Cys‐loop ligand‐gated ion 
channel superfamily, which also encompasses nicotinic acetylcholine receptors (nAChRs), 
glycine receptors, and 5‐hydroxytryptamine type‐3 (5‐HT3) receptors [65, 68–70]. The diverse pharmacology displayed by GABAA receptors sets them apart from the rest of the family and is clinically relevant targets for anticonvulsant, anxiolytic, and sedative drugs [65, 69]. 
Typically, GABAA receptors are heteropentameric structures composed of five different sub‐units (α1‐6, β1‐3, Υ1‐3 (Υ2S, Υ2L), ρ1‐3, δ, ε, θ, and π), each containing four transmembrane 
domains (TM1‐4) (Figures 5 and 6). Five out of twenty‐one available subunits comprise the 
complex, forming a pore from the TM2 segments [67–70]. The top three most common struc‐
tural compositions in the brain are α1β2γ2, α2β3γ2, and α3β3γ2, with the likely stoichiometry 
of 2α:2β:1γ [65, 67, 69].
Benzodiazepines potentiate the inhibitory effects of GABA by allosterically altering the 
receptor and increasing its affinity for GABA [67]. Benzodiazepine‐insensitive receptors are 
formed when the γ subunit is replaced by δ, ε, or π [69]. Rho (ρ) subunits are unique because 
these subunits predominately co‐assemble together to form homo‐ and hetero‐oligomers. 
Previously, ρ oligomers were classified as GABA
C
 receptors, but more recently are consid‐
ered a subclass of GABAA receptors. Even though GABAA and GABAC receptors are structur‐ally very similar to one another, these receptors formally fell into two different groups based 
on their differential pharmacology and physiology [69, 70]. A major difference between the 
A and C subtypes are that GABAA receptors are selectively blocked by bicuculline and modu‐lated by benzodiazepines, steroids, and barbiturates. GABA
C
 receptors are not sensitive to 
the same drugs, but rather are blocked by 1,2,5,6‐tetrahydropyridin‐4‐yl) methylphosphinic 
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acid (TPMPA) and activated by Z‐4‐amniobut‐2‐enoic acid [cis‐aminocrotonic acid (CACA)]. 
Additionally, GABA
C
 receptors exhibit a higher sensitivity to GABA, conduct less current, 
have longer channel opening times, and desensitize slower in the presence of an agonist. 
GABA
C
 receptors, however, are no longer classified as a separate division, but are now con‐
sidered a GABAA‐ρ subclass because they are exclusively constructed of ρ subunits [70].
GABAB receptors are metabotropic Ca2+ or K+ channels, conducting slow inhibitory neu‐rotransmission, in which a ligand (i.e., GABA) binds and indirectly induces pore opening 
through G‐protein coupling activation and second messenger signaling [64, 67, 68] (Figure 7). 
Functional GABAB receptors exist as heterodimers composed of one GABAB(1) (1a‐g) and one GABAB subunit [70]. The GABAB(1) subunit binds to GABA and is mandatory for functional receptors, whereas the GABAB2 subunit is responsible for G‐protein coupling and signaling. The most prevalent GABAB isoforms are GABAB(1a) and GABAB(1b), which are highly conserved across species. Other isoforms, 1c‐g, have also been identified, but are either species‐specific 
or do not exist naturally [64]. Baclofen, clinically used as a muscle relaxant, stimulates GABAB receptors, which are otherwise insensitive to drugs that modulate the GABAA receptors [67].
Figure 5. GABAA receptor structure and cross‐section. GABAA receptors contain five subunits, typically in the ratio of 2α:2β:1γ, with the transmembrane domain 2 (TM2) forming the chloride‐permeable pore. Each subunit consists of four 
hydrophobic transmembrane domains with the N‐ and C‐ terminus facing the extracellular side. The GABA binding 
site is located at the interface between α and β subunit, while the benzodiazepine (BZs) binding site sits at the junction 
between α and γ. GABA binding triggers channel opening, allowing inward chloride ion flux, whereas benzodiazepine 
binding potentiates the GABA‐induced chloride influx [65, 69] (Modified from Jacob et al. [65] and Vithlani et al. [69]).
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Figure 6. GABAA receptor transmembrane topology. Each subunit consists of four transmembrane domains. The N‐ and C‐terminus lie on the extracellular side, with the N‐terminus being the site of action for several drugs. A large 
intracellular domain exists between TM3 and TM4, providing a hub for a majority of the protein‐protein interactions as 
well as posttranslational modifications (palmitoylation, ubiquitination, phosphorylation) [65, 69].
Figure 7. GABAB receptor structure. GABAB receptors are heterodimers composed of either a 1a or 1b subunit and a mandatory 2 subunit. GABAB receptors are G‐protein coupled and are activated by the ligand GABA, which binds to the 1 subunit. Following GABA ligand binding, G‐protein activation induces opening of postsynaptic potassium channels 
and closing of presynaptic calcium channels, hyperpolarizing the target cell (Modified from Emson [64]).
Schizophrenia Treatment - The New Facets14
13. Distribution
GABAA subunit expression has been well characterized in the rat brain [66]. Several subunits exhibit broad expression throughout the nervous system, fluctuating across development and 
regions. However, a few subunits demonstrate regional or cell‐type specificity. For example, 
α6 subunit is exclusively expressed in cerebellar granule cells and the ρ subunit is largely 
restricted to the retina. Peripheral expression of GABAA receptors has been demonstrated 
in the liver, smooth airway muscles, the lung, immune cells, and the intestines [68]. GABAB 
receptors are localized in the striatum, brainstem, thalamus, hippocampus, cerebellum, and 
cortex. The 1b subunit is the most prevalently expressed across all brains regions, except for 
the striatum in which the 1a subunit is the most abundant [64].
14. Parvalbumin interneurons and the prefrontal cortex
The prefrontal cortex (PFC) is the neuroanatomical hub for executive functions such as 
working memory, which can be metaphorically thought of as the brain's blackboard [21, 71]. 
Incoming stimuli are transiently stored, manipulated, updated, and guide goal‐directed 
behavior [72]. Working memory is dependent on prefrontal circuitry involving the unique 
balance between pyramidal Delay excitatory neurotransmission and GABAergic interneu‐
ronal inhibition [57, 62, 71]. Excitatory Delay cells become activated upon presentation of a 
salient cue and sustain neuronal activity throughout a delay period, essentially ‘remember‐
ing’ the cue, and allowing an appropriate response. For instance, Figure 8 represents an 
Figure 8. Single unit electrophysiological activity of a Delay cell in the primate DLPFC during a working memory task. 
The onset of Delay cell activity is triggered by the presence of relevant stimuli, or a cue. In the absence of a visual 
cue, Delay cells persistently fire during the delay period and allow for the generation of a goal‐directed response 
(e.g., saccade). The sustained neuronal firing during the delay period is hypothesized to be the neural correlate of 
working memory and depends on both excitatory pyramidal activity as well as fast‐spiking GABAergic interneurons in 
the DLPFC [21, 71, 73, 74] (Modified from Monaco et al. [21]).
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example of single unit prefrontal Delay cell activity in the primate dorsolateral prefrontal 
cortex (DLPFC) during an oculomotor delayed‐response task. In this working memory task, 
subjects are trained to fix their gaze at the center. A single cue is presented somewhere in the 
360° perimeter, followed by a brief delay period in which the cue is absent. After the delay 
period, an appropriate response would be an eye saccade in the direction that the cue was 
first presented.
Working memory, the sustained neuronal activity that occurs during the delay, is not only 
dependent on prefrontal pyramidal cells, but also fast‐spiking GABAergic interneurons 
[57, 62, 71]. Pharmacological evidence supports the importance of fast‐spiking interneu‐
rons in the DLPFC for working memory function. Administration of a GABAAR antagonist, bicuculline, lead to impaired mnemonic tuning during an oculomotor delayed‐response 
task. Therefore, working memory, particularly sustained neuronal activity during the 
delay period, depends on GABAA receptors. Furthermore, GABAergic hypofunctioning in the DLPFC partly contributes to working memory deficits [62, 75]. GABAergic neuro‐
nal activity and its role in working memory function are also connected to gamma oscilla‐
tions. Gamma oscillations, which fall in the band range between 30 and 60 Hz, are required 
for working memory function. A research study conducted in 2003 reported that gamma 
band oscillations increased proportionally with working memory load [57, 62, 76]. More 
specifically, fast‐spiking PV interneurons are a crucial input for gamma rhythm genera‐
tion. Inhibition of PV interneurons attenuates gamma oscillations, whereas driving PV 
 neuronal activity  initiates gamma‐frequency rhythms [62]. Excitatory pyramidal output in 
the prefrontal cortex is modulated by inhibitory gamma oscillations, largely driven my PV‐
interneurons, essentially fine‐tuning the circuit and allowing for proper working memory 
function. Conclusively, PFC‐dependent working memory involves a symbiotic balance 
between excitatory pyramidal output and fast inhibitory activity of PV‐interneurons, which 
shapes and fine‐tunes the circuit.
15. Parvalbumin interneuronal hypofunctioning in schizophrenia
Schizophrenia is a debilitating neurodevelopmental disorder in which afflicted individu‐
als suffer from cognitive impairments, working memory deficits being a core feature. 
Unfortunately, available medications poorly treat cognitive symptoms albeit cognitive 
performance most strongly determines functional outcomes. Working memory function 
requires fast and synchronous inhibition of pyramidal neuronal networks within the pre‐
frontal cortex, which is regulated by GABAergic neurotransmission. Because individuals 
afflicted with schizophrenia display reduced frontal cortical gamma oscillatory power in the 
DLPFC during a working memory task and cognitive impairments are a core feature, dis‐
rupted GABAergic signaling is highly implicated in the pathology of this disorder [57, 62]. 
Glutamic acid decarboxylase (GAD), the enzyme that synthesizes GABA and PV prefrontal 
expression is reduced in schizophrenia, further demonstrating a GABA deficit in this neuro‐
anatomical region [57, 62, 77–79].
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NMDARs have been demonstrated to be vital throughout neurodevelopment, with NR2A 
specifically involved in the maturation and maintenance of GABAergic PV interneurons. 
A  previous study showed that NR2A hypofunction leads to reduced GAD67 expression and 
PV immunoreactivity [59]. It is important to note that the reduction in parvalbumin is not due 
to density (i.e., interneuronal cell number), but rather a decrease in protein level expression. 
Researchers hypothesized that this suppressed expression in GAD67, and therefore PV, leads to 
GABAergic malfunctioning or hypofunctioning [57, 59, 62, 77]. Interestingly, GAD65, the other 
isoform, does not demonstrate such impairments. Cortical levels of GABA remained unaltered 
in animals without GAD65, thus demonstrated specificity to the GAD67 isoform [57, 62, 80]. 
Reductions in GAD67, however, are associated with decreased GAD enzymatic activity as 
well as GABA levels in the cortex [62, 81]. Individuals suffering from schizophrenia were also 
reported to have increases in the α2 subunit of GABAA receptors and decreased GABA trans‐porter 1 (GAT1) levels. GAT1 are proteins important for the removal of GABA from the synaptic 
cleft, while the GABAA α2 subunit is highly concentrated at the axon initial segment of pyrami‐
dal neurons and mediate fast synaptic inhibitory neurotransmission (Figure 9). Therefore, this 
Figure 9. Comparison of normal and schizophrenia synaptic connection at the junction between a parvalbumin 
chandelier interneuron (PVCh) and a pyramidal axon initial segment. A core feature of schizophrenia is GABergic 
deficits; in the rebalanced circuitry, presynaptic expression of GABA transporter 1 (GAT1) on the axonal terminals of 
the GABAergic interneurons is decreased, while the expression of GABAAα2 receptors at the axon initial segments of pyramidal neurons is increased (Modified from Lewis et al. [62] and Lewis et al. [57]).
The Convergence of Glutamate and GABA Dysregulation in Schizophrenia
http://dx.doi.org/10.5772/65870
17
inverse correlation is speculated to act as a compensatory  mechanism to increase the effect of 
GABA on postsynaptic cells and return the circuitry back to homeostatic conditions [57, 62, 82].
However, what remains to be unanswered is which proceeds which: NMDA receptor hypo‐
functioning or GABAergic deficits. In order to understand how cognitive impairments in 
schizophrenia emerge, we must first uncover the molecular underpinnings that lead to the 
root of these dysfunctions.
16. Current GABA‐targeted therapeutics
In individuals afflicted with schizophrenia, a compensatory mechanism to balance the circuit 
naturally gets set into motion. In order to offset the shift towards excitation, GAT1 is reduced 
presynaptically and GABAAα2 receptors are increased postsynaptically. These changes result in levels of GABA remaining in the synaptic cleft longer and more postsynaptic receptors 
available for activation. GABA Aα2 receptor agonists offer as a promising therapeutic to phar‐macologically target the pathophysiological inhibitory deficit in the DLPFC [62]. GABAAα2 receptors are predominately located at the axon initial segment of pyramidal neurons and 
therefore should exhibit limited off‐target effects on other domains [83]. GABAAα2‐selective 
benzodiazepines are a likely candidate because these agents would only activate and poten‐
tiate GABAAα2 receptors in the presence of GABA, preventing dysregulated inhibition that would otherwise result from direct activation of these receptors. Treatment with GABAAα2‐selective benzodiazepines might also offer an additive benefit of reducing anxiety in patients, 
due to the anxiolytic effects that are mediated by GABAAα2 receptors [62, 84]. In aims to provide better treatment options, further research is warranted to elucidate the underlying 
mechanism of GABAergic hypofunctioning, which largely contribute to working memory 
deficits seen in schizophrenia.
17. Summary
Working memory is a key executive function that guides an organism's response by filter‐
ing out important information from the external environment and applying relevant details 
towards a goal‐directed behavior. This process requires the output of a specialized circuit 
localized within the prefrontal cortical circuits. The synchrony between excitatory pyrami‐
dal Delay cells, which produce the necessary persistent neuronal activity, and fast‐spiking 
GABAergic neurotransmission, which in turn shape and fine‐tunes the pyramidal cell out‐
put, underlies working memory. Both the excitatory and inhibitory components (such as 
NMDARs and GABAARs) are crucial in the maintenance of this delicate process, and dys‐
regulation of either likely serves as a pathophysiological process in schizophrenia. Working 
memory deficits are a core feature of schizophrenia with NMDA and GABA hypofunctioning 
highly implicated in the etiology of the disease. Future research is warranted for further deci‐
phering whether NMDA hypofunctioning precedes GABAergic deficits or vice versa.
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